U.S. Healthcare Services Stock News

Why Celldex Therapeutics (CLDX) is on investors’ radar today Celldex Therapeutics (CLDX) has drawn attention after recent trading, with shares last closing at $29.51 and showing mixed returns over the past week, month, past 3 months, and year. See our latest analysis for Celldex Therapeutics. Recent trading has been choppy, with a 30 day share price return of 28.30% and a 1 year total shareholder return of 44.52%, set against a weaker 3 year total shareholder return of 29.47% and a 5 year...

Recent share performance and business snapshot Titan America (TTAM) has drawn attention after a one month return showing a 16.1% decline, extending a past 3 months slide of 7.8%. This has prompted investors to reassess the cement and building materials producer. The Brussels based company reports annual revenue of US$1.65b and net income of US$178.46m, with recent revenue growth of 6.3% and net income growth of 13.7%. This has put a spotlight on how earnings support the current share...

IDEAYA Biosciences (IDYA) enrolled the first patient in its Phase 1 IDE892 trial for MTAP-deleted solid tumors and updated investors on its broader MTAP-deletion and CDKN2A-deficiency pipeline. The company also trimmed certain combination studies. See our latest analysis for IDEAYA Biosciences. The latest IDE892 trial update comes after a 1-month share price return of 9.32% and a 1-year total shareholder return of 78.09%, suggesting recent momentum on top of already strong longer term...

Earlier this month, Jones Lang LaSalle unveiled its Accelerate 2030 plan, pairing new long-term financial targets with an enlarged share repurchase authorization of US$4.40 billion, including a US$200 million accelerated buyback. This combination of technology-led growth ambitions and a very large capital return commitment marks a meaningful shift in how JLL is positioning itself for clients and shareholders through 2030. Next, we’ll consider how JLL’s significantly expanded share buyback...

Setting the scene on U.S. Physical Therapy With no fresh headline event driving U.S. Physical Therapy (USPH) today, investors are left weighing a share price of $76.83 alongside recent return figures and the company’s latest reported revenue and net income. See our latest analysis for U.S. Physical Therapy. The recent share price pullback, including a 1-day share price return of 1.35% decline and a 30-day share price return of 11.63% decline, sits alongside a 1-year total shareholder return...

In early March 2026, AAON reported fourth-quarter 2025 results showing US$424.22 million in sales and full-year earnings per share of US$1.29, while also affirming a regular quarterly dividend of US$0.10 per share payable on March 30, 2026. At the same time, AAON highlighted its Alpha Class EXTREME SERIES rooftop unit’s success in the U.S. Department of Energy’s HVAC Technology Challenge, underlining how advanced dual-fuel heat pump capability and cold-weather performance could reinforce...

Wix.com Ltd. recently reported its fourth-quarter 2025 results, showing revenue of US$524.27 million and a net loss of US$40.23 million, alongside full-year 2025 revenue of US$1.99 billion and net income of US$50.65 million. On the same day, Wix.com issued mid-teens percentage revenue growth guidance for both the first quarter and full year 2026 and secured a US$250,000,000 private placement featuring warrants and lock-up agreements with Durable Capital Partners and other investors,...

In recent months, Driehaus Capital Management and Deerfield Management Company have sharply increased their holdings in Praxis Precision Medicines, adding hundreds of thousands of shares and committing a combined investment of more than US$346.79 million as the company filed two FDA new drug applications for ulixacaltamide and relutrigine. This combination of larger institutional ownership, advancing late‑stage neuroscience candidates and a cash position supported by roughly US$1.55 billion...

Earlier in March, Federated Hermes announced that four of its investment strategies received LSEG Lipper Fund Awards 2026 US for consistently strong risk‑adjusted performance, while CEO J. Christopher Donahue is scheduled to present at the RBC Capital Markets Global Financial Institutions Conference 2026 in New York on March 11. This combination of third‑party recognition and high recent earnings growth and return on equity is sharpening attention on how effectively Federated Hermes converts...

In early March 2026, Clarivate Plc announced it had integrated its Cortellis Regulatory Intelligence data with Anthropic’s Claude via the open Model Context Protocol, giving biopharma, biotech, medtech and clinical research organizations context-aware access to authoritative regulatory data directly within their existing AI workflows. This move highlights how Clarivate is aiming to embed its validated regulatory content deeper into customers’ day-to-day decision processes, potentially...

In March 2026, Silvaco Group, Inc. completed a follow-on at-the-market US$15 million common stock offering and reported full-year 2025 revenue of US$63.06 million with a net loss of US$41.21 million, alongside guidance for first-quarter 2026 revenue of US$15 million to US$19 million. A few days earlier, the company also announced the immediate availability of Mixel MIPI Production Ready Offerings, broadening its silicon-proven mixed-signal interface IP portfolio across advanced process nodes...

EHang Holdings Limited reported its fourth-quarter 2025 results on March 12, 2026, with sales rising to CNY 243.78 million and quarterly net income reaching CNY 10.49 million, while full-year 2025 revenue increased to CNY 509.50 million alongside a full-year net loss of CNY 230.54 million. The shift from a quarterly net loss in the prior year to profitability in Q4 2025, even as the full year remained loss-making, highlights a meaningful improvement in operating performance and cost...

Why Evercore (EVR) is on investors’ radar today Evercore (EVR) has drawn fresh attention after a period of mixed share performance, with a recent 0.4% daily gain that contrasts with weaker moves over the past week, month, and past 3 months. See our latest analysis for Evercore. That 0.4% 1 day share price gain comes after a tougher spell, with a 7.2% 7 day share price decline and a 23.6% year to date share price decline, even though the 1 year total shareholder return is 35.1% and the 3 year...

Wynn Resorts has resumed construction on its US$5.10 billion Wynn Al Marjan Island integrated resort in Ras Al Khaimah, UAE, after a brief security-related pause, while maintaining close coordination with US and UAE authorities to safeguard employees and operations. This restart reinforces Wynn’s push into the Middle East through a 40% stake in the project, marking the region’s first large-scale casino resort and expanding its luxury hospitality footprint beyond existing US and Asia...

If you are wondering whether Enova International at around US$134.11 is still offering value or already pricing in a lot of optimism, you are asking the right question for this stock. The share price has seen a 2.5% decline over the last 7 days and a 10.1% decline over the last 30 days, although the 1 year return sits at 44.8% and the 3 year return is 220.5%, with 5 year returns at 266.4%. Recent coverage of Enova International has focused on its position within the diversified financials...

On Holding (NYSE:ONON) is back in focus after releasing its 2025 results and outlining 2026 guidance, with management expecting at least 23% constant currency net sales growth to a minimum CHF 3.44b. See our latest analysis for On Holding. The latest guidance and 2025 numbers arrive after a softer patch for the shares. The 30 day share price return is 16.12%, and the year to date share price return is a 19.08% decline. However, the 3 year total shareholder return of 75.80% shows that longer...

Earlier this month, Surgery Partners, Inc. reported 2025 results showing higher sales of US$885.0 million for the fourth quarter and US$3.31 billion for the year but continuing net losses, issued softer 2026 revenue guidance of US$3.35 billion to US$3.45 billion, launched a new US$200.0 million share repurchase program, and appointed veteran health system executive Lloyd Dean as an independent director. These developments, alongside pressure from activist investor Ortelius Advisors pushing...

Why Autodesk (ADSK) Is Back in Focus Autodesk (ADSK) is back on investors’ radar after management reported better than expected quarterly results, announced a 7% workforce reduction, and signaled higher investment in AI, cloud, and construction platforms. See our latest analysis for Autodesk. Autodesk’s US$251.17 share price reflects a mixed year, with a 30 day share price return of 8.63%, a 90 day share price return of 14.66%, and a year to date share price return of 12.40%. The 3 year total...

Corvus Pharmaceuticals stock moves after recent performance swings Corvus Pharmaceuticals (CRVS) has been drawing fresh attention as its share price reflected sharp recent moves, including a 4.3% decline over the past day and a month return that is roughly 17.9% lower. See our latest analysis for Corvus Pharmaceuticals. Even with the latest 4.3% one day share price decline and a softer 30 day share price return of 17.9%, Corvus Pharmaceuticals still shows strong upward momentum, with a 90 day...

If you are wondering whether Coherent is still fairly priced after its run, you are not alone. Many investors are now asking what the current share price actually reflects. The stock most recently closed at US$242.76, with reported returns of 3.0% over 7 days, 11.8% over 30 days, 24.9% year to date, a very large 1 year return, and a multi-year return above 7x over 3 years and 251.5% over 5 years. Recent news coverage has focused on Coherent's position in photonics and laser technologies,...

Emerson Electric (EMR) has drawn fresh attention after reporting quarterly earnings that exceeded analyst expectations, raising full year earnings guidance and outlining plans for a US$250 million buyback and US$10 billion in shareholder returns by 2028. See our latest analysis for Emerson Electric. Despite the earnings beat and higher guidance, recent share price returns have been soft, with a 30 day share price return of 10.73% and a year to date share price return of 2.64%. In contrast,...

Recent analyst commentary on New Oriental Education & Technology Group (EDU) has focused on its valuation and cash flow metrics. It has highlighted how these measures compare with sector averages and has tied that information to a constructive earnings outlook. See our latest analysis for New Oriental Education & Technology Group. The recent 1-day share price return of 0.73% and 7-day share price return of 2.28% sit against a 30-day share price decline of 8.23% and year to date share price...

Winmark Corp recently passed the Caviar Cruise quality investing screen, which highlights companies with durable competitive strengths, high profitability, and solid financial health. This recognition emphasizes Winmark’s franchise-based model, where high returns on invested capital and strong cash flow conversion underpin its operational quality. We’ll now examine how Winmark’s very high return on invested capital shapes the company’s investment narrative following these quality-focused...

Why Verisk’s new buyback is drawing fresh attention Verisk Analytics (VRSK) has come back into focus after launching a $1.5b accelerated share repurchase program and stepping up investor outreach through an Analyst and Investor Day plus back to back conference appearances. See our latest analysis for Verisk Analytics. The 1 month share price return of 11.04% and 1 day move of 1.61% to US$201.22 sit against a 1 year total shareholder return of 29.73% decline. The recent buyback announcement...